Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration’s (FDA) plan to reduce, refine or ...

FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency.

In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...